<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300036</url>
  </required_header>
  <id_info>
    <org_study_id>829/62</org_study_id>
    <nct_id>NCT04300036</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Longan Syrup in Healthy Volunteers With Insomnia</brief_title>
  <acronym>longan</acronym>
  <official_title>Efficacy and Safety of Longan Syrup in Healthy Volunteers With Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study were to evaluate efficacy and safety of longan syrup in healthy
      volunteers with insomnia. Subjects will take 15 ml of longan syrup once a day for 3 months.
      They will be investigated their insomnia using Insomnia Severity Index (ISI) questionnaire,
      Thai- The Pittsburgh Sleep Quality Index (PSQI) questionnaire,STOP - BANG questionnaire,
      Epworth Sleepiness Scale (ESS) questionnaire, Actiwatch, plasma cortisol, aspartate
      transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), creatinine (Cr),
      blood urea nitrogen (BUN), fasting blood sugar, HbA1C, complete blood count (CBC),
      hemoglobin, lipid profile, phosphate level, saliva cortisol, and urine melatonin before and
      after taken longan syrup.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">February 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insomnia severity index</measure>
    <time_frame>3 months</time_frame>
    <description>Insomnia severity index after taken longan syrup will be less than before taken. The minimum and maximum values are 0 and 28 scores, respectively. Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thai- The Pittsburgh Sleep Quality Index</measure>
    <time_frame>3 months</time_frame>
    <description>Thai- The Pittsburgh Sleep Quality Index after taken longan syrup will be less than before taken. The minimum and maximum values are 0 and 21 scores, respectively. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Snoring, Tiredness, Observed apnea, blood Pressure, Body mass index, Age, Neck circumference and Gender questionaire</measure>
    <time_frame>3 months</time_frame>
    <description>Snoring, Tiredness, Observed apnea, blood Pressure, Body mass index, Age, Neck circumference and Gender questionaire (STOP - BANG) after taken longan syrup will not be more than before taken. The minimum and maximum values are 0 and 8 scores, respectively. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth sleepiness scale</measure>
    <time_frame>3 months</time_frame>
    <description>Epworth sleepiness scale after taken longan syrup will be less than before taken. The minimum and maximum values are 0 and 24 scores, respectively. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actiwatch value</measure>
    <time_frame>3 months</time_frame>
    <description>Actiwatch value after taken longan syrup will be better than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cortisol</measure>
    <time_frame>3 months</time_frame>
    <description>Serum cortisol value at 8.00 o'clock (normal value 5-23 mcg/dL) after taken longan syrup will not be less than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saliva cortisol</measure>
    <time_frame>3 months</time_frame>
    <description>Saliva cortisol at 20.00 o'clock (normal value 3.9 +/- 0.2 nmol/L (range 2.2-4.1 nmol/L)) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Melatonin</measure>
    <time_frame>3 months</time_frame>
    <description>Urine Melatonin overnight (in ng/mL) after taken longan syrup will not be less than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Low-density lipoprotein</measure>
    <time_frame>3 months</time_frame>
    <description>Serum Low-density lipoprotein (in mg/dL) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum High-density lipoprotein</measure>
    <time_frame>3 months</time_frame>
    <description>Serum High-density lipoprotein (in mg/dL) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>Serum total cholesterol (in mg/dL) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triglyceride</measure>
    <time_frame>3 months</time_frame>
    <description>Serum triglyceride (in mg/dL) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycohemoglobin</measure>
    <time_frame>3 months</time_frame>
    <description>Glycohemoglobin (Hemoglobin A1c) (in %) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>3 months</time_frame>
    <description>Fasting plasma glucose (in mg/dL) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase in serum</measure>
    <time_frame>3 months</time_frame>
    <description>Aspartate aminotransferase (in U/L ) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase in serum</measure>
    <time_frame>3 months</time_frame>
    <description>Alanine aminotransferase (in U/L ) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase in serum</measure>
    <time_frame>3 months</time_frame>
    <description>Alkaline phosphatase (in U/L ) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>3 months</time_frame>
    <description>Serum creatinine (in mg/dl ) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Urea Nitrogen</measure>
    <time_frame>3 months</time_frame>
    <description>Blood Urea Nitrogen (in mg/dl ) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>3 months</time_frame>
    <description>Hemoglobin (in g/dl ) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphate level</measure>
    <time_frame>3 months</time_frame>
    <description>Phosphate level (in g/dl ) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete blood count</measure>
    <time_frame>3 months</time_frame>
    <description>Complete blood count (in 10^6 cells/mcl ) after taken longan syrup will not be more than before taken.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>longan syrup</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take 15 ml of longan syrup once a day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo syrup</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Take 15 ml of placebo syrup once a day for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>longan syrup</intervention_name>
    <description>Subjects will take 15 ml of longan syrup once a day for 3 months</description>
    <arm_group_label>longan syrup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo syrup</intervention_name>
    <description>Subjects will take 15 ml of placebo syrup once a day for 3 months</description>
    <arm_group_label>Placebo syrup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 35-65 years

          -  Insomnia severity index (ISI) more than 7

          -  Thai- The Pittsburgh Sleep Quality Index (PSQI)) more than 5

          -  STOP - BANG less than 5

          -  No diabetes mellitus and thyroid dysfunction

          -  Fasting plasma glucose less than 126mg/dl

          -  Can communication (reading and writing)

          -  Be willing to be subjects in this study

        Exclusion Criteria:

          -  Know longan allergy or have history of adverse events from longan

          -  Take benzodiazepine, melatonin, valerian, and St Johns Wort in 1 month before this
             study starting

          -  Take medicines, herbs, or food supplements including thiazide diuretics, beta-blockers
             ,and estrogen that have an effect on blood sugar level in 1 month before this study
             starting

          -  Cannot control comorbidity diseases

          -  Irregular working hours

          -  Pregnancy or breast feeding

          -  Participated in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pornanong Aramwit, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pornanong Aramwit, Ph.D</last_name>
    <phone>+66899217255</phone>
    <email>aramwit@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn Unviersity</name>
      <address>
        <city>Bangkok</city>
        <zip>10310</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>March 7, 2020</last_update_submitted>
  <last_update_submitted_qc>March 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Pornanong Aramwit, Pharm.D., Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>longan</keyword>
  <keyword>insomnia</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

